Brigatinib Plus Local Consolidative Therapy Shows Promise in ALK+ NSCLC
Chul Kim, MD Associate Professor Georgetown University School of Medicine Washington, DC KEY TAKEAWAYS FROM CHUL KIM, MD The ALTA-1 trial showed benefit of brigatinib over crizotinib in all patients with ALK-positive lung cancer and those with brain …